Belzutifan is an inhibitor of HIF-2α, which is used to treat RCC associated with VHL. It helps cut down tumor hypoxia signaling. The drug comes in film-coated tablet form.
Each tablet is 40 mg strong. The suggested dosage is 120 mg taken every day. The stuff is usually sold in bottles that hold 90 tablets.
